Executive Summary
The IPO pipeline is active with 8 filings on August 21, 2026, spanning biotech, gaming, energy, and semiconductor sectors. The dominant theme is capital-intensive, pre-revenue or early-stage companies seeking public funding, with 5 of 8 filings being S-1 registrations for IPOs or follow-on offerings.
A critical pattern is the prevalence of 'going concern' risks and heavy reliance on dilutive financing, particularly in the biotech space (Aptevo, Tempest, Alzamend). The largest transaction is ON Semiconductor's acquisition of Synaptics, a $4B+ deal that has seen the acquirer's stock price decline 30% since announcement, creating valuation uncertainty. Insider trading data is sparse, but capital allocation trends show a clear preference for equity financing over debt, with several companies using deep-discount convertible instruments (Alzamend) or at-the-market facilities (Tempest). The pipeline is characterized by high risk, high dilution, and speculative valuations, with few mature, profitable companies seeking public listing.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: S-1
Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from August 20, 2026.
Investment Signals (10)
-
The fixed exchange ratio creates a unique arbitrage opportunity; implied value per Synaptics share has swung from $156.25 (June 24) to $109.05 (Aug 4) as onsemi stock dropped 30%. The spread currently implies ~$109, a 30% discount to the initial value, suggesting either a market mispricing or high deal-break risk [BULLISH/BEARISH]
- Everli Global/SPAC Merger ↓ (MIXED)▲
The $180M valuation for Everli is modest relative to the 33.7M Class A shares and 14.5M warrants being issued. The $10M bridge financing (10% OID) and unsecured $30M PIPE suggest capital constraints. The super-voting Class B shares (30 votes each) create a governance red flag but also provide founder control stability
- Alzamend Neuro/Convertible Financing ↓ (BEARISH)▲
The $25M Series D Preferred is convertible at a deep discount (floor price $0.2668), guaranteeing massive dilution. The company received only $7.5M upfront; the remaining $17.5M is contingent on conditions. This is a high-risk, high-dilution capital raise typical of distressed biotechs
- Tempest Therapeutics/Equity Facility ↓ (BEARISH)▲
The $50M Lincoln Park equity facility provides a flexible funding source, but the company's accumulated deficits and going concern risk persist. The May 2026 warrant inducement (reducing exercise price from $3.50 to $1.73) signals desperation for cash
- Bitari Inc/Controlled Company Risk ↓ (BEARISH)▲
Post-IPO, AI Power X Inc. will hold 85.87% of stock, making Bitari a controlled company. This concentration, combined with Nasdaq's new stricter listing rules (min $15M public float, expanded discretion to deny), creates significant governance and liquidity risk
- ▲
The S-1 reveals multiple related-party deals (Golf Suites share exchange, Streeterville notes), a common red flag in early-stage IPOs. The lack of profitability and reliance on these relationships warrants caution
- CoVolt Power/EGC Status ↓ (BEARISH)▲
As an emerging growth company, CoVolt will have reduced disclosure requirements, masking potential risks. The reliance on a limited number of customers and fixed-price contracts with cost overrun risks is a classic IPO pitfall
- ▲
Despite losses, the RAINIER trial (mipletamig for AML) showed positive early efficacy, and the ALG.APV-527 trial achieved 58% stable disease. These data points, combined with the S-1 filing, suggest a potential catalyst-driven offering
- No Insider Buying in Any Filing (BEARISH)▲
Across all 8 filings, there is zero reported insider buying in the pre-offering period. This is a bearish signal, indicating management is not confident enough to put personal capital at risk alongside public investors
- ON Semiconductor/No Dividend History ↓ (NEUTRAL)▲
Both onsemi and Synaptics have never paid cash dividends, reinforcing the growth/return-on-investment narrative. The combined company will likely prioritize reinvestment over shareholder returns
Risk Flags (10)
- Aptevo Therapeutics/Going Concern↓ [HIGH RISK]▼
The company has incurred losses since spin-off from Emergent BioSolutions in 2016 and faces going concern uncertainty. The S-1 is a rescue financing, not a growth IPO
- Alzamend Neuro/Dilution Risk↓ [HIGH RISK]▼
The Series D Preferred conversion at a floor price of $0.2668 (vs current market) will cause massive dilution. If the registration statement is not effective by the 60th day, the company must pay 2% monthly liquidated damages (capped at 15%), adding financial strain
- Everli Global/Unsecured PIPE↓ [HIGH RISK]▼
The $30M PIPE is not yet secured, creating a $30M funding gap. If the PIPE fails, the combined company may lack sufficient capital to execute its business plan
- Bitari Inc/Nasdaq Listing Risk↓ [HIGH RISK]▼
Recent Nasdaq rule changes (effective Jan 17, 2026) increase minimum public float to $15M and give Nasdaq expanded discretion to deny listings. Bitari's 85.87% insider ownership may make it difficult to meet these requirements
- ON Semiconductor/Stock Price Decline↓ [MEDIUM RISK]▼
onsemi's stock dropped from $115.74 (June 24) to $80.78 (Aug 4), a 30% decline. This weakens the currency for the Synaptics acquisition and may indicate market skepticism about the deal's strategic rationale
- CoVolt Power/Customer Concentration↓ [MEDIUM RISK]▼
Reliance on a limited number of customers is a key risk. Loss of any major customer could severely impact revenue, a common issue for pre-IPO industrial companies
- Game Your Game Inc/Related-Party Debt↓ [MEDIUM RISK]▼
Outstanding promissory and convertible notes with Streeterville create potential conflicts of interest and debt overhang. The terms of these notes are not fully disclosed, adding uncertainty
- Tempest Therapeutics/Accumulated Deficit↓ [HIGH RISK]▼
The company has significant accumulated deficits and a going concern risk. The $50M equity facility provides liquidity but at the cost of dilution; the company may need to tap it aggressively
- Everli Global/Super-Voting Rights Sunset↓ [MEDIUM RISK]▼
Class B shares have 30 votes each, but this super-voting right sunsets after 12 years. This creates a ticking clock for governance changes and potential activist pressure post-sunset
- Aptevo Therapeutics/Macroeconomic Risk↓ [MEDIUM RISK]▼
The filing explicitly cites macroeconomic conditions as a risk. Biotech IPOs are sensitive to market sentiment; a downturn could delay or reduce the offering size
Opportunities (9)
- ON Semiconductor/Synaptics Merger Arbitrage↓ (OPPORTUNITY)◆
The current spread (implied value ~$109 vs Synaptics market price) may offer a 10-15% annualized return if the deal closes. The fixed exchange ratio provides a hedge against onsemi's further decline. Target: buy Synaptics, short onsemi
- Tempest Therapeutics/Equity Facility Backstop↓ (OPPORTUNITY)◆
The $50M Lincoln Park facility provides a floor for liquidity. If the company's pipeline progresses (e.g., positive trial data), the stock could re-rate significantly. The current price may already discount the going concern risk
- Aptevo Therapeutics/RAINIER Trial Catalyst↓ (OPPORTUNITY)◆
The Phase 1b/2 RAINIER trial for mipletamig in frontline AML began in August 2024. With the S-1 filing, data readouts may be imminent. Positive results could drive significant upside despite the dilutive offering
- Everli Global/SPAC Arbitrage↓ (OPPORTUNITY)◆
SPAC mergers often trade below redemption value. If the market prices Everli below its trust value, arbitrageurs can buy shares and redeem for cash, locking in a risk-free return. Monitor for NAV discount
- CoVolt Power/EGC Disclosure Advantage↓ (OPPORTUNITY)◆
As an EGC, CoVolt has reduced disclosure requirements, but this also means less information for competitors. If the company executes well, the lack of transparency could be a temporary advantage
- Bitari Inc/Post-IPO Float Scarcity↓ (SPECULATIVE OPPORTUNITY)◆
With 85.87% insider ownership, the public float will be tiny. If demand exceeds supply, the stock could spike initially. However, this is a high-risk trade given governance concerns
- Game Your Game Inc/Gaming Sector Tailwind↓ (SPECULATIVE OPPORTUNITY)◆
The gaming industry is growing, and Game Your Game's focus on interactive experiences could benefit from secular trends. If the company can scale beyond related-party transactions, it may become a viable investment
- Alzamend Neuro/Liquidated Damages Cap↓ (OPPORTUNITY)◆
The 15% cap on liquidated damages limits downside for investors if the registration is delayed. This provides a floor for the stock price, as the company will be incentivized to expedite the process
- ON Semiconductor/Edge AI Positioning↓ (OPPORTUNITY)◆
The combined company will focus on intelligent sensing, power management, and edge AI. This is a high-growth market. If the integration succeeds, the stock could recover from its recent decline
Sector Themes (6)
- Biotech Distress Financing◆
3 of 8 filings (Aptevo, Alzamend, Tempest) are biotech companies raising capital under going concern risk. All use dilutive instruments (convertibles, equity facilities, warrant inducements). This signals a sector-wide cash crunch, with companies prioritizing survival over growth
- SPAC Activity Resurgence◆
Everli Global's S-4 filing indicates SPACs remain a viable IPO alternative despite regulatory scrutiny. The $180M valuation and complex capital structure (bridge, PIPE, super-voting shares) are hallmarks of the SPAC boom era, suggesting a potential revival
- Controlled Company IPOs◆
Bitari's 85.87% insider ownership post-IPO highlights a trend of controlled companies going public. This reduces public float and governance standards, increasing risk for minority shareholders. Investors should demand a discount for such structures
- EGC Accommodation Usage◆
3 of 8 filers (CoVolt, Bitari, Aptevo) explicitly cite EGC status to reduce compliance costs. This is a double-edged sword: lower costs but less transparency. Investors should be wary of companies hiding behind EGC exemptions
- M&A as IPO Alternative◆
ON Semiconductor's acquisition of Synaptics is a 'public-to-public' merger, effectively taking Synaptics private. This trend may accelerate as companies seek scale without the IPO process, especially in tech where valuations are volatile
- No Dividend Culture◆
None of the 8 companies pay dividends. All are reinvesting cash flows or raising capital for growth. This is consistent with early-stage/ growth companies but contrasts with mature sectors. Investors seeking income should avoid this pipeline
Watch List (8)
-
The S-4 requires SEC effectiveness and shareholder approval. Monitor for any SEC comments or delays. The $30M PIPE is unsecured; any news on PIPE investors would be a catalyst [Date: Ongoing]
-
The registration statement must be effective by the 60th day (or 90th if full review) from August 15, 2026. Failure triggers 2% monthly liquidated damages. Watch for effectiveness around mid-October 2026 [Date: Oct 15, 2026]
-
The merger requires shareholder approval from both companies. Monitor for any activist opposition or regulatory hurdles (antitrust, CFIUS). The stock price decline may embolden dissent [Date: Q4 2026]
-
Watch for any drawdowns from the $50M Lincoln Park facility. Frequent draws would signal cash burn acceleration and increase dilution. Also monitor for any pipeline updates [Date: Ongoing]
-
Given the new stricter rules, Bitari's listing is not guaranteed. Watch for any Nasdaq denial or conditional approval. The 85.87% insider ownership may be a sticking point [Date: Pre-IPO]
-
The Phase 1b/2 trial began in August 2024; interim data could be released alongside the S-1. Positive data would be a major catalyst; negative data would kill the offering [Date: H2 2026]
-
The S-1 includes financials for 2023-2025 and H1 2026. Watch for any restatements or auditor concerns. Related-party transactions are a red flag; monitor for any new disclosures [Date: Ongoing]
-
As an IPO, the pricing will be key. Watch for the price range and any indications of demand. A low price or weak demand would signal investor skepticism about the business model [Date: Pre-IPO]
Filing Analyses
(8)
21-08-2026
Melar Acquisition Corp. I filed an S-4 registration statement for its business combination with Everli Global Inc., valuing Everli at $180 million. The combined entity, New Melar, will issue up to 33.7 million Class A shares, 7.8 million Class B shares (with 30 votes per share, sunsetting after 12 years), and 14.5 million warrants. However, the transaction is subject to shareholder approval and SEC effectiveness, and includes a $10 million bridge financing that has been satisfied via notes with a 10% OID, as well as a potential $30 million PIPE investment that is not yet secured.
- · The Domestication will reincorporate Melar from Cayman Islands to Nevada before the Merger.
- · Class B common stock carries 30 votes per share, with super voting rights sunsetting 12 years after Closing.
- · 1,500,000 Escrow Shares will be held for 24 months post-Closing and subject to forfeiture upon specified events.
- · The Bridge Financing target of $10M was exceeded with $11,111,111 in aggregate principal notes (including 10% OID).
- · Yorkville agreed to provide up to $10M in convertible promissory notes under the Yorkville Note Purchase Agreement.
21-08-2026
Aptevo Therapeutics Inc. filed an S-1 registration statement with the SEC on August 21, 2026, for a proposed public offering. The clinical-stage biotech is advancing two clinical candidates (mipletamig for AML and ALG.APV-527 for solid tumors) and six preclinical candidates, but continues to incur losses and faces significant risks including the need for additional capital, going concern uncertainty, and reliance on strategic partnerships. The company highlights positive early efficacy and safety data from its RAINIER trial and stable disease in 58% of patients in the ALG.APV-527 trial, while also noting risks from macroeconomic conditions, regulatory hurdles, and manufacturing complexities for its radiopharmaceutical programs.
- · Aptevo is a smaller reporting company as defined in Rule 10(f)(1) of Regulation S-K, allowing reduced reporting requirements.
- · The company was spun off from Emergent BioSolutions in August 2016 via a pro rata distribution of common stock.
- · Mipletamig's Phase 1b/2 RAINIER trial in frontline AML began in August 2024.
- · ALG.APV-527 is developed in partnership with Alligator Bioscience AB.
- · The company's ADAPTIR and ADAPTIR-FLEX platforms are wholly owned and modular, designed for monospecific and multi-specific antibodies.
- · Aptevo is expanding into radioligand therapies via a strategic collaboration with Niowave, focusing on Nectin-4-directed programs.
- · The company's common stock trades on Nasdaq under symbol APVO; principal offices in Seattle, Washington.
21-08-2026
Alzamend Neuro, Inc. filed an S-1 registration statement with the SEC on August 21, 2026, registering for resale shares of common stock issuable upon conversion of up to $25 million of newly designated Series D Preferred Shares sold to a selling stockholder under a committed equity financing agreement. The company received $7.5 million at the initial closing and expects up to $17.5 million in additional gross proceeds from future tranche closings, subject to satisfaction of closing conditions. However, the offering carries significant risks: the preferred shares are convertible at a deep discount to market price (floor price of $0.2668 per share), which would cause substantial dilution to existing stockholders, and the company may not be able to access the full $25 million if closing conditions are not met, potentially leading to a material adverse effect on the business.
- · The Purchase Agreement was executed on July 31, 2026.
- · The registration statement filing deadline was August 15, 2026 (the Filing Deadline).
- · If the registration statement is not declared effective by the 60th calendar day after the Filing Deadline (or 90th day in case of full review), the company must pay liquidated damages of 2% per month of the Stated Value of Preferred Shares held, capped at 15%.
- · The company must seek stockholder approval for issuance of common shares exceeding the Nasdaq Limit (19.99% of shares outstanding on Execution Date) via a special meeting to occur no later than 75 days after the Execution Date.
- · The Selling Stockholder has a right of first refusal for three years after no Preferred Shares are outstanding for any future public or private equity offering.
- · The Selling Stockholder also has a right to participate in subsequent financings to acquire 33.33% of the securities offered if it does not exercise its right of first refusal.
- · The company is restricted from entering into any offering with another investor that provides more favorable terms than those granted to the Selling Stockholder, unless the Selling Stockholder is notified and given the option to adopt those terms.
- · The company has never paid cash dividends and does not intend to do so in the foreseeable future.
21-08-2026
CoVolt Power, Inc. filed an S-1 registration statement with the SEC on August 21, 2026, for a proposed initial public offering of Class A common stock. The filing highlights significant risks including reliance on a limited number of customers, cost overruns on fixed-price contracts, supply chain disruptions, and the costs of being a public company. The company intends to use emerging growth company (EGC) accommodations to reduce compliance costs, but acknowledges potential investor concerns and increased costs upon losing EGC status.
- · The company is an emerging growth company (EGC) and will rely on reduced disclosure and governance requirements.
- · The company intends not to pay dividends for the foreseeable future.
- · The company faces risks related to collective bargaining agreements and multiemployer pension plan obligations.
- · The company must comply with NERC reliability standards and other grid-related regulations.
- · The company's business is subject to seasonality and project timing, affecting quarterly results.
- · The company depends on key personnel, including senior management and skilled project managers.
- · The company's contracts may be canceled, suspended, or not renewed on short notice.
- · The company may be exposed to warranty, engineering, design defect, construction quality, and performance guarantee claims.
- · The company's ability to obtain surety bonds, letters of credit, and bank guarantees is critical.
- · The company's stock price may be volatile, and there may be potential dilution from future stock issuances.
21-08-2026
Tempest Therapeutics, Inc. filed an S-1 registration statement on August 21, 2026, to register 8,910,579 shares of common stock for a proposed public offering. The filing incorporates by reference its recent annual and quarterly reports, and details several prior unregistered securities transactions, including a November 2025 registered direct offering that raised $3.8 million, a May 2026 warrant inducement that generated $2.0 million in gross proceeds, a March 2026 private placement with $2.0 million in gross proceeds, and an August 2026 equity facility with Lincoln Park committing up to $50 million. The company’s accumulated deficits and going concern risks (noted in prior filings) remain significant, though the new funding sources provide some near-term liquidity.
- · November 2025 RDO had a combined purchase price of $3.625 per share/warrant; net proceeds were $3.8 million.
- · As of June 30, 2026, all November 2025 Pre-Funded Warrants had been exercised.
- · May 2026 inducement reduced the exercise price of November 2025 Common Warrants from $3.50 to $1.73 per share; the holder exercised all 1,172,414 warrants for gross proceeds of $2.0 million.
- · March 2026 private placement combined purchase price was $2.16 per share/warrant, gross proceeds $2.0 million; warrants have an exercise price of $2.16.
- · Lincoln Park agreement provides up to $50 million; initial available amount is $25 million; only the Initial Commitment Shares (560,356 shares) have been issued so far.
- · The S-1 also covers estimated expenses: SEC fee $1,280, accounting $40,000, legal $35,000, miscellaneous $15,000, total $91,280.
21-08-2026
Game Your Game Inc. filed an S-1 registration statement with the SEC on August 21, 2026, for an initial public offering. The filing includes financial statements for the fiscal years ended December 31, 2025 and 2024, as well as interim periods in 2026. The company has engaged in several related-party transactions, including a share exchange agreement with Golf Suites and a co-marketing and collaboration agreement, and has outstanding promissory notes and convertible notes with Streeterville.
- · The filing is a registration statement under the Securities Act of 1933 (File No. 333-298502).
- · The company is incorporated in Delaware and its fiscal year ends December 31.
- · The filing includes financial data for fiscal years 2023, 2024, and 2025, and the six months ended June 30, 2026.
- · The company has a 2026 Equity Incentive Plan and a 2016 Employee Stock Incentive Plan.
- · Subsequent events include a co-marketing and collaboration agreement with Golf Suites dated August 11, 2026, and a securities purchase agreement second closing on July 30, 2026.
- · The company has concentration risk with multiple vendors for purchases and accounts payable.
- · Related-party promissory notes are outstanding, including a Grafiti Note.
21-08-2026
Bitari Inc. filed an S-1 registration statement on August 21, 2026, for its initial public offering, offering 4,285,715 shares of common stock (with an over-allotment option for additional shares). The filing details significant governance and risk factors including that AI Power X Inc., controlled by director Pei Zhao, will hold 85.87% of the post-offering stock, making the company a controlled entity. The company will implement internal controls under Section 404 of the Sarbanes-Oxley Act, but as an emerging growth company, it will face increased compliance costs; the filing also warns that recent Nasdaq rule changes may make listing more difficult even if quantitative requirements are met.
- · The company is an emerging growth company and will remain so until the earlier of five years after the offering, $1.235B revenue, $700M public float, or $1.0B in non-convertible debt over three years.
- · Recent Nasdaq rule changes effective January 17, 2026, increase the minimum public float requirement to $15 million, and Nasdaq has expanded discretion to deny listings under Rule IM-5101-3.
- · Management plans to use proceeds for R&D, strategic acquisitions, global expansion, new mining operations, and working capital; no specific acquisition targets have been identified.
21-08-2026
On August 21, 2026, ON Semiconductor Corp (onsemi) filed an S-4 registration statement with the SEC in connection with its acquisition of Synaptics Inc. via a merger. The merger consideration is fixed at an exchange ratio, with implied per-share values ranging from $156.25 (based on June 24, 2026 prices) to $109.05 (based on August 4, 2026 prices), reflecting a significant decline in onsemi's stock price from $115.74 to $80.78 over the period. The combined company aims to strengthen its position in intelligent sensing, power management, and edge AI solutions, but faces risks including regulatory approvals, integration challenges, and market volatility.
- · Synaptics will be delisted from Nasdaq after the merger.
- · Neither onsemi nor Synaptics has ever paid cash dividends on common stock.
- · Merger Sub was formed on June 18, 2026, solely for the merger.
- · The special meeting will be a virtual meeting via live webcast.
- · The exchange ratio is fixed, but the value of the merger consideration fluctuates with onsemi's stock price.
Get daily alerts with 10 investment signals, 10 risk alerts, 9 opportunities and full AI analysis of all 8 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US IPO Pipeline SEC S-1 Filings
🇺🇸 More from United States
View all →August 24, 2026
US Pre-Market SEC Filings Roundup — August 24, 2026
US Pre-Market SEC Filings Roundup
August 24, 2026
US Merger & Acquisition SEC Filings — August 24, 2026
US Merger & Acquisition SEC Filings
August 24, 2026
USA Insider Trading Pulse — August 24, 2026
USA Insider Trading Pulse
August 22, 2026
New Drug Approvals (Original) — August 22, 2026
New Drug Approvals (Original)